An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms
出版年份 2018 全文链接
标题
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms
作者
关键词
-
出版物
Future Oncology
Volume 14, Issue 2, Pages 137-150
出版商
Future Medicine Ltd
发表日期
2017-10-23
DOI
10.2217/fon-2017-0298
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2017) C N Harrison et al. LEUKEMIA
- Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
- (2017) Iram Saeed et al. Expert Review of Hematology
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Emerging treatments for classical myeloproliferative neoplasms
- (2016) Alessandro M. Vannucchi et al. BLOOD
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- Ruxolitinib treatment for GvHD in patients with myelofibrosis
- (2016) Y Mori et al. BONE MARROW TRANSPLANTATION
- The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
- (2016) Ruben Mesa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognosis of Primary Myelofibrosis in the Genomic Era
- (2016) Prithviraj Bose et al. Clinical Lymphoma Myeloma & Leukemia
- Safety considerations when treating myelofibrosis
- (2016) J. M. O’Sullivan et al. Expert Opinion On Drug Safety
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
- (2016) Enrico Maffini et al. Journal of Hematology & Oncology
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2016) Ruben Mesa et al. Journal of the National Comprehensive Cancer Network
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib
- (2015) L. Pieri et al. BLOOD
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
- (2015) Adam J. Mead et al. BRITISH JOURNAL OF HAEMATOLOGY
- The evolution and clinical relevance of prognostic classification systems in myelofibrosis
- (2015) Prithviraj Bose et al. CANCER
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
- (2015) Cecilia Arana Yi et al. Future Oncology
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
- (2015) Koji Sasaki et al. LEUKEMIA & LYMPHOMA
- Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
- (2015) Holly L. Geyer et al. MEDIATORS OF INFLAMMATION
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
- (2014) Lisa Pieri et al. AMERICAN JOURNAL OF HEMATOLOGY
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
- (2014) John T. Reilly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
- (2014) S. C. Meyer et al. CLINICAL CANCER RESEARCH
- Safety evaluation of ruxolitinib for treating myelofibrosis
- (2014) Sofia Galli et al. Expert Opinion On Drug Safety
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Hepatitis B virus reactivation associated with ruxolitinib
- (2013) Chien-Heng Shen et al. ANNALS OF HEMATOLOGY
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms
- (2013) Neha Bhagwat et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guideline for the diagnosis and management of myelofibrosis
- (2012) John T. Reilly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started